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ABSTRACT 
Elucidating the poorly defined mechanisms by which inflammatory lesions are spatially 
restricted in vivo, is of critical importance in understanding skin disease. Chemokines are the 
principal regulators of leukocyte migration and are essential in the initiation and maintenance 
of inflammation. The membrane-bound psoriasis associated atypical chemokine receptor 
ACKR2 binds, internalises and degrades most pro-inflammatory CC-chemokines. Here we 
investigate the role of ACKR2 in limiting the spread of cutaneous psoriasiform inflammation 
to sites that are remote from the primary lesion.  Circulating factors capable of regulating 
ACKR2 function at remote sites were identified and examined using a combination of 
clinical samples, relevant primary human cell cultures, in vitro migration assays and the 
imiquimod-induced model of psoriasiform skin inflammation. Localised inflammation and 
IFNγ together upregulate ACKR2 in remote tissues, protecting them from the spread of 
inflammation. ACKR2 controls inflammatory T-cell chemotaxis and positioning within the 
skin, preventing an epidermal influx that is associated with lesion development. Our results 
have important implications for our understanding of how spatial restriction is imposed on 
the spread of inflammatory lesions, and highlight systemic ACKR2 induction as a therapeutic 
strategy in the treatment and prevention of psoriasis and potentially a broad range of other 
immune-mediated diseases.  
Keywords: psoriasis / ACKR2 / chemokine / T-cell / IFNgamma / inflammation / imiquimod  
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INTRODUCTION 
Chemokines, the primary in vivo regulators of leukocyte migration, are central to 
inflammatory pathogenesis (Rot and von Andrian, 2004; Zlotnik and Yoshie, 2000). They 
bind to 7-transmembrane spanning receptors to orchestrate the recruitment of inflammatory 
cells into and within tissues. Importantly, in addition to the classical signalling chemokine 
receptors(Bachelerie et al., 2014a), there exists a subfamily of stromally-expressed atypical 
chemokine receptors that display promiscuous ligand binding and atypical signalling 
responses following ligand binding(Bachelerie et al., 2014b; Graham et al., 2012; Nibbs and 
Graham, 2013). These atypical chemokine receptors can function as chemokine-scavengers 
thereby fine-tuning or limiting chemokine responses in vivo. One of these molecules, 
Atypical Chemokine Receptor 2 (ACKR2; previously known as D6), is a high-affinity 
receptor for multiple inflammatory CC-chemokines (Graham and Locati, 2013). ACKR2 
does not mount classical signalling responses following ligand binding (Borroni et al., 2013) 
but internalises ligands and targets them for intracellular degradation (Weber et al., 2004). 
ACKR2 has therefore been characterised as a scavenging-receptor for inflammatory CC-
chemokines. ACKR2’s role in limiting the development of inflammation is demonstrated by 
numerous studies in ACKR2-deficient mice as well as by reports of aberrant expression 
patterns in human inflammatory pathologies (Bazzan et al., 2012; Cochain et al., 2012; 
Codullo et al., 2011; Singh et al., 2012).  
Recently, we demonstrated that ACKR2 expression is particularly elevated in 
uninvolved skin of psoriatic patients (Singh et al., 2012). We hypothesised that inflammatory 
products from primary inflamed lesions limit the spread of chemokine-dependent 
inflammation by driving systemic upregulation of ACKR2 at remote sites. Here, we present 
experimental in vitro and in vivo validation of, and a mechanistic explanation for, our 
hypothesis. We highlight circulating products of the primary inflamed site, notably Th1/Th17 
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cytokines, as inducers of remote ACKR2 expression. We demonstrate an anti-inflammatory 
role for increased ACKR2 expression at remote non-inflamed sites in vivo and provide a 
mechanism whereby focal inflammation reduces the propensity for inflammation to spread to 
remote tissues through modulation of ACKR2. Overall, we propose that dynamic regulation 
of ACKR2 expression is an endogenous means for limiting spread of psoriasiform 
inflammation.  
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RESULTS 
ACKR2-deficient mice display exaggerated inflammation in response to imiquimod. 
 To established a mouse model appropriate for assessing the mechanism of differential 
ACKR2 regulation, and the role of ACKR2 in regulating localised inflammation, we 
determined the role of ACKR2 in the well-characterised imiquimod (IMQ) mouse model of 
psoriasis(van der Fits et al., 2009). At rest, there are no histological differences in wild-type 
(WT) and ACKR2-deficent skin (Baldwin et al., 2013; Jamieson et al., 2005; Nibbs et al., 
2007). However, in response to daily topical IMQ application (Aldara™ cream), and 
compared to WT mice, ACKR2-deficient mice displayed an exaggerated cutaneous 
inflammatory response (Figure 1A). This was associated with significantly increased 
epidermal thickness (Figure 1B and Supplementary Figure 1A) and keratinocyte proliferation 
(Figure 1C and Supplementary Figure 1B). The dynamics of psoriasis-like pathology during 
induction of inflammation was quantified using a modified Psoriasis Area Severity Index 
(PASI) (Supplementary Figure 2A), which demonstrated that ACKR2-deficient mice rapidly 
develop substantially worse pathology than WT (Figure 1D). This was accompanied by 
significantly more weight loss in ACKR2-deficient mice (Figure 1D). Importantly, the PASI 
score correlated directly with the extent of epidermal thickness and keratinocyte proliferation, 
which were both significantly enhanced in ACKR2-deficient mice (Figure 1E). Together, 
these data demonstrate that ACKR2 is required for limiting inflammation in a relevant in vivo 
model of psoriasis. 
 
ACKR2 regulates chemokine mediated T-cell migration to control the positioning of 
CD3+ T-lymphocytes in vivo.  
T-cell migration into the epidermis is essential for the development of psoriasiform 
inflammation (Conrad et al., 2007). We therefore determined the effect of ACKR2 on CD3+ 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 6 
T-cell localisation in the IMQ model. There are no basal differences in total cutaneous, or 
epidermal, T-cell numbers in ACKR2-deficient, compared to WT, mice (Baldwin et al., 
2013; Jamieson et al., 2005). However, there was an increase in CD3+ T-cell numbers in skin 
of imiquimod inflamed WT and ACKR2-deficient mice, compared to vehicle-treated mice 
(Figure 2A). Also, whilst T-cells were, in the main, excluded from inflamed WT epidermis 
(Figure 2A-C), they were able to migrate efficiently into inflamed ACKR2-deficient 
epidermis, even in areas of epidermis overlying dermis that exhibited relatively few T-cells 
(Figure 2A and Supplementary Figure 3).  
Next, to understand the mechanism by which ACKR2 controls T-cell localisation in 
vivo, we tested whether ACKR2 expressed by a barrier layer of keratinocytes (as seen in the 
skin dermo-epidermal junction) could regulate human T-cell migration. For this purpose, we 
established an in vitro 3D cell migration assay. The T-cell chemoattractant chemokine 
CCL20 has been associated with psoriasis (Lowes et al., 2014). However, CCL20 does not 
bind to ACKR2(Madigan et al., 2010) and thus will not contribute to the altered T-cell 
localisation. We therefore developed an assay utilising the ACKR2 ligand CCL5, which is 
highly expressed in human psoriatic plaques (Singh et al., 2012) and is a potent attractant for 
human T-cells (Makino et al., 2002). CCL5 was placed at the top of a skin collagen matrix, 
below which we placed a 'barrier' layer of primary human keratinocytes that separated the 
chemokine from the T-cells at the bottom of the collagen-filled chamber (Supplementary 
Figure 4). Cultured keratinocytes express low ACKR2 at rest, but can be induced to express 
very high levels (see Figure 3A and 3C). While a barrier of low ACKR2 expressing 
keratinocytes had little influence on T-cell migration towards CCL5, high ACKR2 expressing 
IFNγ-stimulated keratinocytes effectively blocked directional migration of T-cells towards 
the chemokine (Figure 2D). Together, this indicates that the upregulation of ACKR2 in the 
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barrier layer of basal keratinocytes prevents CCL5-induced directional T-cell migration into 
the epidermis.  
We next wanted to determine whether ACKR2 expression is differentially modulated 
in the in vivo IMQ model of psoriasis. We found that localised cutaneous inflammation was 
associated with significantly increased ACKR2 transcript expression in apparently 
'uninvolved' tissues, located away from the primary site of inflammation, including heart and 
liver (Figures 2E). Importantly we noted no gross histological abnormalities in these tissues 
in either WT or ACKR2-/- mice treated with or without IMQ (Supplementary Figure 5). We 
refer to such sites (especially cutaneous sites) as being 'remote’ from the primary 
inflammatory lesion. In contrast, no differences were seen in ACKR2 transcript expression in 
lymph nodes draining either inflamed, or non-inflamed, cutaneous sites (Figure 2F). Notably, 
and in keeping with our data from human psoriasis (Singh et al., 2012), ACKR2 expression 
was reduced within psoriasis-like inflammatory lesions of IMQ-treated skin compared to 
non-inflamed skin (Figure 2G). However, and in contrast to the data for heart and liver, no 
significant differences in cutaneous ACKR2 mRNA expression were seen in skin remote 
from the site of IMQ treatment (Figure 2G).  
Together, our data demonstrate that ACKR2 determines localisation of inflammatory 
T-cells at sites of inflammation and that localised inflammation, induced by IMQ, leads to 
remote up-regulation of ACKR2 expression in non-inflamed tissues.  
 
Th1/Th17 cytokines induce ACKR2 expression in epidermal keratinocytes and protect 
cutaneous sites from inflammation. 
 Increased epidermal ACKR2 expression in human uninvolved psoriatic skin, and 
psoriatic peripheral blood leukocytes (PBL) (Singh et al., 2012), suggests regulation of 
expression by systemic circulating factors derived from inflammatory plaques. To gain 
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insights into these factors in vivo we performed multiplex analysis on plasma from healthy 
controls and psoriatic patients. The most striking, and significant, differences in psoriatic 
patients were seen with levels of cytokines strongly associated with activated Th1 and Th17 
phenotypes (Supplementary Figure 6). We therefore tested whether Th1/Th17 cytokines 
could increase ACKR2 mRNA expression in healthy primary human keratinocytes. 
Treatment of keratinocytes with cytokine cocktails, representative of Th1 and Th17 cells, 
increased ACKR2 transcript expression (Figure 3A). In addition, and as previously reported 
(Singh et al., 2012), IFNγ was active as a potent, single-agent, inducer of ACKR2 mRNA 
expression.  
 We then examined the impact of addition of variable numbers of activated T-cells on 
ACKR2 transcript expression in an in vitro 'human skin-equivalent' model of psoriasis (van 
den Bogaard et al., 2014). As shown (Figure 3B), activated T-cells dose-dependently 
increased ACKR2 expression in this model and the T-cell dependency of this effect was 
confirmed using ciclosporin A (Figure 3C). Next, we collected total conditioned medium 
from in vitro activated T-cells, which markedly increase keratinocyte ACKR2 mRNA 
expression in a dose-dependent manner (Figure 3D). To assess the relative contribution of 
IFNγ, tissue culture supernatant of activated human T-cells was treated with anti-IFNγ 
antibodies, which neutralised the potent ACKR2-inducing effect (Figure 3E). As T-cell 
derived factors are major regulators of keratinocyte ACKR2 expression, we additionally 
assessed levels of these factors in plasma of IMQ-treated mice. Surprisingly, our analysis 
showed that IFNγ levels were below the limits of detection of the assays. In addition, we did 
not detect IFNγ expression within the inflammatory lesions in IMQ-treated mice (Figure 3F). 
Thus, while the IMQ mouse model recapitulates key aspects of the cutaneous pathology of 
human psoriasis, it is not associated with elevated IFNγ expression and does not recapitulate 
the high circulating IFNγ levels observed in patients (Supplementary Figure 6). We therefore 
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systemically injected IFNγ (as a prototypic cytokine with ACKR2-inducing properties and in 
order to better model human disease) into mice, which led to a significant increase in ACKR2 
expression in dorsal skin (Figure 3G). 
We next wanted to determine if increased ACKR2 could protect mice from 
developing inflammation in response to IMQ treatment. Because IFNγ is deficient in the IMQ 
model of psoriasis, and thus incompletely recapitulates human disease, IFNγ was injected 
into mice twice daily throughout the IMQ treatment protocol and the extent of inflammation 
determined. As shown (Figure 3H), IFNγ administration was associated with reduced signs of 
inflammation in WT mice following IMQ treatment and, using our modified PASI, this 
reduction was shown to be significant (Figure 3I). In addition, ELISA analyses revealed no 
impact of IMQ, or IFNγ on IFNγ expression within the inflamed skin (in keeping with Figure 
3F) but demonstrated up-regulation of the T-cell chemoattractant chemokines CCL5 and 
CCL20, which was blocked in response to systemic IFNγ treatment (Supplementary Figure 
7). CCL20 protein expression was also induced in ACKR2-deficient mice following IMQ 
treatment (Supplementary Figure 7) and this was also reduced by IFNγ treatment. In keeping 
with the reported inhibitory effects of IFNγ on Th17 cell differentiation (Harrington et al., 
2005; Park et al., 2005), IL-17 levels were reduced in IMQ-inflamed skin in response to IFNγ 
treatment (Supplementary Figure 7). Importantly, ACKR2 transcript levels in treated skin 
displayed a strong inverse correlation with the PASI, supporting the conclusion that systemic 
(IFNγ-driven) increases in ACKR2 expression ameliorated cutaneous inflammatory 
pathology (Figure 3J).  
 
Remote cutaneous inflammation, together with IFNγ, induces systemic up-regulation of 
ACKR2 and limits the spread of inflammation. 
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 In order to determine the effect of localised inflammation on remote cutaneous 
ACKR2 expression, we examined the impact of local IMQ treatment of skin with concurrent 
systemic IFNγ administration on remote skin ACKR2 expression. Systemic administration of 
IFNγ led to significant increases in cutaneous ACKR2 expression at the local site of both 
control cream and IMQ treatment (Figure 4A). Importantly, while IMQ treatment alone did 
not result in increased ACKR2 transcript levels at remote cutaneous sites (Figure 2G and 
4A), IMQ combined with systemic IFNγ significantly increased ACKR2 expression in 
remote skin to levels higher than those seen with IFNγ alone (Figure 4A), thus successfully 
replicating the human psoriatic expression pattern of ACKR2. To examine the sustained 
impact of IFNγ/IMQ upregulation of remote ACKR2 expression on subsequent cutaneous 
inflammatory responses, we initially treated a primary skin site (right flank) with IMQ with 
concurrent systemic administration of vehicle control or IFNγ. The IMQ and IFNγ treatment 
was stopped at day 4 and from that point onwards a second remote non-inflamed cutaneous 
site (left flank) was treated with topical IMQ (experimental design summarised in Figure 4B). 
Note that mice receiving either vehicle or IFNγ in the absence of IMQ treatment displayed no 
skin inflammation and had a PASI score of 0. These, essentially negative, data are not 
included in subsequent figures. As expected from the above data, systemic 
IFNγ administration reduced pathology at the primary treatment site (Figure 4C) which 
plateaued at day 5 in the vehicle-treated mice but at Day 8 in the IFNγ-treated mice. Whilst 
we have no clear explanation for the increased PASI score in the IFNγ-treated mice between 
days 5 and 8, these data may also indicate a role for IFNγ in delaying the inflammatory 
process. Notably, following cessation of IFNγ/IMQ at the primary site, subsequent IMQ-
induced inflammation at the remote site (contralateral flank skin) was reduced in mice 
receiving both IMQ and IFNγ for the initial 4 days (Figure 4D). We obtained similar data in 
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which initial systemic IFNγ in WT mice significantly reduced the inflammatory response to 
IMQ when using the ear as a distal site of inflammation (Figure 4E). Q-PCR revealed that 
localised psoriasiform inflammation and IFNγ co-ordinately up-regulated remote tissue 
ACKR2 transcript levels (Figure 4F), and that this occurred predominantly in the epidermal 
layer (Figure 4G). Importantly, to confirm that the remote protective effect of systemic IFNγ 
is mediated specifically by ACKR2, experiments were also conducted in ACKR2-deficient 
mice. As predicted, and in contrast to WT mice, IFNγ did not confer a protective effect at 
either the initial (Figure 4H), or remote (Figure 4I), IMQ treatment sites in ACKR2-deficient 
mice. In fact, at some time points, IFNγ administration exacerbated pathology suggesting that 
in ACKR2-deficient mice with their inherent inability to regulate inflammatory CC-
chemokine activity, IFNγ-induced chemokine expression can contribute to pathology.  
In agreement with the above data, we found that IFNγ-mediated ACKR2 up-
regulation significantly protected mice against IMQ-induced epidermal thickening, limited 
epidermal hyperproliferation and led to a relative exclusion of T-cells from the epidermis at 
the both the primary site and secondary site of IMQ-application (Figures 5A and B and 
Supplementary Figure 8). When the ear was investigated as a remote site in ACKR2-/- mice 
(as in Figure 4E), IFNγ was seen to have no apparent effect with the IMQ treatment leading 
to increased dermal/epidermal thickening, enhanced keratinocyte proliferation and greater 
epidermal T cell recruitment compared to IMQ-treated WT ear skin (Supplementary Figure 
9). More detailed analysis of the phenotypes of the T-cells infiltrating the whole skin 
(Supplementary Figure 10A) and epidermis (Supplementary Figure 10B) indicated that there 
were no differences in the overall numbers of each of the phenotypic subsets identified 
entering the whole skin in response to IMQ in the presence, or absence, of systemic IFNγ. In 
addition, examining the T-cell populations specifically within the epidermal compartment 
revealed the anticipated increase in CD3+ T-cell numbers in IMQ-treated ACKR2-deficient 
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mice and further showed that this was heavily skewed towards the CD4+ T-cell subset. 
Importantly, differences in epidermal CD3+ cell numbers in IFNγ and vehicle control treated 
mice were not simply reflective of differences in total cutaneous T-cell numbers (Figures 5C-
F), but instead represented a specific skin-wide positioning of T-cells that excluded them 
from the epidermal compartment. Thus, these data demonstrate that localised psoriasiform 
inflammation, together with elevated circulating IFNγ, as seen in human psoriasis, protects 
distal sites from inflammation, and that this occurs in an ACKR2-dependent manner.  
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DISCUSSION 
Mechanistic interactions between localised inflammatory responses and remote tissues are 
poorly understood. Here we provide evidence that one site of localised inflammation can 
protect remote tissues from further inflammatory triggers, through induced upregulation of 
the chemokine scavenging receptor ACKR2. Our model of local and remote ACKR2 function 
is summarised in Figure 6. 
As the main regulators of leukocyte migration, chemokine function is highly 
regulated. This includes regulation by ACKR2 through its ability to bind, internalise and 
degrade pro-inflammatory CC-chemokines (Weber et al., 2004). In psoriasis, ACKR2 is 
highly upregulated in clinically unaffected remote skin (Singh et al., 2012).  Here our data 
show that remote upregulation of ACKR2 occurs by soluble mediators released from 
inflammatory lesions, and that this limits spread of inflammation to tissues remote to the 
original lesion. Our results show that psoriasiform pathology is exaggerated in the absence of 
ACKR2, with significantly more CD3+ T-cells localised to the epidermis. Previous work has 
shown epidermal CD3+ T cells to be crucial for the development of psoriatic lesions (Conrad 
et al., 2007) and CCL5 to be implicated in their accumulation in the epidermis (Collins et al., 
2016; Fukuoka et al., 1998). Importantly, ACKR2 may also contribute to the epidermal (and 
dermal) accumulation of other inflammatory leukocytes attracted by CC-chemokines and thus 
whilst our data focus on epidermal T cells, they may have broader relevance for 
inflammatory cell involvement in pathogenesis. Thus, we provide a mechanism by which a 
pathology-induced decrease in ACKR2 function can lead to uncontrolled T-cell (and possibly 
other leukocyte) epidermal entry, and hence exaggerated inflammatory lesion development. 
Strikingly, we found that IMQ-induced inflammation at one site, when supplemented with 
psoriasis-associated IFNγ to more closely mimic human disease, was able to modulate 
induction of new lesions at a second, remote site. Remote sites exhibited increased ACKR2 
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expression that correlated with restricted epidermal T-cell entry and skin thickening. The 
ability of systemic IFNγ to increase ACKR2 expression, in the context of a mouse pathology 
that does not otherwise involve IFNγ suggests that these observations are of relevance to both 
IFNγ-dependent and independent inflammatory diseases. In IFNγ-dependent contexts, if 
systemic levels are high enough, IFNγ from the inflamed site may regulate ACKR2 in remote 
areas to limit the inflammatory spread. In IFNγ-independent pathologies, systemic 
administration of IFNγ can achieve the same end. Interestingly, our data provides a 
mechanistic explanation for the previously described therapeutic efficacy of systemic 
IFNγ administration in inflammatory diseases including psoriasis(Cannon et al., 1989; 
Fierlbeck and Rassner, 1990; Fierlbeck et al., 1990; Morhenn et al., 1987; Stevens et al., 
1998; Veys et al., 1997). However, the use of IFNγ for the purpose of upregulating ACKR2 
in humans is likely to be fraught with difficulties, not least due to possible pro-inflammatory 
off-target effects and likely injection site reactions(Johnson-Huang et al., 2012).  
Accordingly, we propose that developing novel, specific inducers of ACKR2 chemokine 
scavenging provides a new therapeutic approach to treat diseases such as psoriasis, and 
possibly other systemic inflammatory disorders. Critically, remote sites were not protected 
from developing lesions by IFNγ in the absence of ACKR2, confirming that this observed 
protective effect is dependent on ACKR2. This is, to our knowledge, is the first 
demonstration that primary lesions can modulate the propensity of other sites to become 
inflamed and that this occurs in an ACKR2-dependent manner.  
 Together our data suggest that remotely increasing ACKR2 expression levels limits 
development of cutaneous inflammatory responses and therefore highlight a potential 
therapeutic role, in psoriasis and other inflammatory diseases, for agents capable of inducing 
ACKR2 expression. 
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MATERIALS AND METHODS 
 
Mouse model of psoriasis 
 The IMQ mouse model was carried out as described (van der Fits et al., 2009). All 
mouse experiments were performed under the auspices of a UK Home Office licence and 
with permission from the University of Glasgow Ethics Committee. 6-8 week old WT (from 
Charles River) and ACKR2-deficient (Jamieson et al., 2005) mice on a C57BL/6J 
background were used throughout the study. A minimum of 6 mice were used per group in 
each of the experiments. IFNγ-treated mice received murine IFNγ (R&D systems) 10,000 or 
20,000U either i.p. or s.c twice daily (as indicated in figures). IFNγ was reconstituted in 
0.01% sterile BSA in PBS (Sigma-Aldrich). Mice were assessed daily and skin inflammation 
scored using a modified Psoriasis Severity Index (Supplementary Figure 2). Ear thickness 
was measured using digital callipers on day of cull. 
 All tissues for RNA extraction were stored in RNAlater (Life Technologies) for 24 
hours at 4°C. For long-term storage, RNAlater-treated tissues were stored at -80°C. Tissues 
for histology and immunohistochemistry were fixed in 10% neutral buffered formaldehyde 
(Sigma).  
 
RNA extractions and Quantitative PCR 
 RNA was extracted and purified on RNeasy Micro columns with on-column DNAse 
digestion as per manufacturer’s instructions. Q-PCR was performed as described in the 
Supplementary Methods section.  
  
Sections and immunohistochemistry 
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 For H&E, Ki67 and CD3+ staining, paraffin-embedded fixed skin was cut to 2 micron 
thickness. Heat-induced antigen-retrieval was performed in pH6 sodium citrate buffer for 100 
seconds at 125°C under pressure. Polyclonal rabbit anti-human CD3 (1:100 dilution) and 
Polyclonal rabbit anti-Ki67 (1:400) (both Dako), or negative controls, were used and 
counterstained with haematoxylin. 
 
T cell and keratinocyte growth and stimulation and generation of human skin 
equivalents. 
Details are provided in the Supplementary methods section. 
 
Migration assay 
Details are provided in the Supplementary Methods section.  
 
Luminex analysis of human plasma. 
Details are provided in the Supplementary Methods section.  
 
Dermal-epidermal splitting 
 Full thickness mouse skin was submerged in 0.025mM EDTA (LifeTechnologies) at 
37°C, after which the epidermal layer was curetted off, leaving the dermis intact. Both skin 
components were immediately lysed in Qiazol, using a Qiagen TissueLyser LT (Qiagen) 
 
Statistics 
 Results are given as mean ± SEM unless otherwise indicated. Student’s t-test, Mann-
Whitney U tests, One-way ANOVA, two-way ANOVA and correlation tests were performed 
in Prism Version 7.0 (GraphPad Software Inc), with multiple comparisons tests as 
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appropriate. Vector data were assessed by the Rayleigh test for vector data in chemotaxis 
plugin in ImageJ (http://imagej.nih.gov/ij/). P<0.05 was deemed significant. * P<0.05, ** 
P<0.01, *** P<0.005, **** P<0.0001. All data is n≥3 and given as Mean ± SEM unless 
otherwise stated.  
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FIGURE LEGENDS 
Figure 1. ACKR2-deficient mice display an exaggerated psoriasiform phenotype in 
response to IMQ treatment.  
a) WT mice treated for 3 days (culled day 4) with vehicle control (top), IMQ (middle), IMQ 
treated ACKR2-deficient mice (bottom). Scale bars: 1cm. 
b) H&E stained WT and ACKR2-deficient (KO) skin after 3 days of IMQ treatment and 
quantification of epidermal thickness after 3 or 6 days of daily IMQ. (Scale bars:100µm; 
Statistics: one-way ANOVA).  
c) Ki67 stained WT and ACKR2-deficient (KO) skin after 3 days of IMQ and quantification 
of thickness of Ki67 staining in the epidermis.  
d) PASI skin inflammation (top). Weight change (baseline=100%) throughout treatments 
(bottom). Statistics: two-way ANOVA, Tukey’s multiple comparisons test, MCT.  
e) Correlation between mean epidermal thickness and PASI score (left). Correlation between 
mean thickness of Ki67+ve epidermis and PASI score (right).  
 
Figure 2. ACKR2 regulates T cell migration and positioning in the skin. 
a) CD3+ staining after 3 days IMQ. Arrows: CD3+ T-cells. Red line: dermal-epidermal 
junction.  
b) distance of CD3+ cells from basement membrane after 3 days IMQ. Two-way ANOVA, 
Sidak’s MCT. 
c) Epidermal CD3+ as percentage total CD3+ cells (One-way ANOVA, Tukey’s MCT).  
d) T-cell migration towards CCL5 (top of plots) across low or high ACKR2-expressing 
keratinocytes. Plots on left: cumulative migration direction. Plots on right: individual tracks 
(black=towards, red=away from CCL5). Statistics: Rayleigh test.  
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e) ACKR2 expression in heart and liver from vehicle (black bars) or IMQ (grey bars) treated 
mice. 
f) ACKR2 expression in draining lymph nodes from treated or untreated skin. Mice were 
treated 3 days with vehicle (black bars) or IMQ (grey bars). 
g) ACKR2 at site of vehicle/IMQ treatment and distal dorsal skin. 
 
Figure 3. Cytokines from activated T-cells induce ACKR2 expression in human 
keratinocytes.  
a-c) ACKR2 expression in response to cytokines (100ng/ml) in human keratinocytes (a), skin 
equivalents treated with with activated CD4+ T-cells (M=million) (b) and skin equivalents 
after 2-4 days with/without treatment with all-trans retinoic acid or ciclosporin A (c).   
d-e) ACKR2 expression in human keratinocytes treated with T-cell conditioned medium 
alone (d) and human keratinocytes treated with anti-IFNγ antibodies (e). Two-way ANOVA, 
Tukey’s MCT.  
f) Mouse IFN-γ expression 24 hours after treatment. Virus-infected samples act as positive 
control. One-way ANOVA, Tukey’s MCT. 
g) ACKR2 expression in mouse dorsal skin following IFNγ treatment (20,000U/day for 4 
days, n=6). Student’s t-test.  
h) WT mice were treated for 3 days and photographed on day 4. Scale bars: 1cm. 
i) PASI score. Arrows: first day of IFNγ/PBS injections and IMQ/vehicle.  
j) Correlation of cutaneous ACKR2 expression and PASI score.  
 
Figure 4. Localised IMQ combined with systemic IFNγ ameliorates psoriasis-like 
pathology at both primary and distal sites, in an ACKR2 dependent manner.  
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a) ACKR2 expression (day 5) in treated and distal/remote untreated skin of IMQ-treated mice 
(days 1-4) in presence/absence of systemic IFNγ (20,000U/day). Statistics: Student's t-test. 
b) Experimental design. 
c-d) PASI score at initial lesions (c) and lesion induced by IMQ at second site (d).  
e) As above with ear as second site. Ear thickness was measured in mice treated on the flank 
with IMQ and systemic IFNγ (20,000U/day) or PBS. 
f) ACKR2 expression in second IMQ-induced lesions. First IMQ lesion was induced with 
concurrent PBS (grey bar) or IFNγ (black bar). Statistics: Student’s t-test.  
g) ACKR2 expression in distal epidermis and dermis. Epidermal/dermal separation 
confirmed by involucrin Q-PCR (grey bars). Statistics: Student's t-test. 
(h-i) PASI score of IMQ-treated ACKR2-deficient mice pre-treated with systemic PBS or 
IFNγ (20,000U/day) at initial lesion (h) and at secondary lesion (i).  Statistics: two-way 
ANOVA. 
 
Figure 5: Histological and immunochemical analysis of primary and secondary IMQ-
treated skin sites.  
a,b) Representative images of H&E, Ki67, CD3+ staining, and associated quantification of: 
a) Initial IMQ-induced lesion with concurrent PBS or systemic IFNγ (day 5). 
b) Second IMQ-induced lesion initiated following cessation of initial IMQ/IFNγ or PBS 
treatment (day 8. As in Fig 4b). In CD3+ images; dark red arrows=epidermal CD3+ T-cells, 
dark red line=dermal-epidermal junction. All scale bars=100µm. 
c-f) Total CD3+ T-cell numbers in IMQ-induced skin lesion with concurrent PBS or systemic 
IFNγ in first lesion (c,d) or second lesion following cessation of systemic PBS or IFNγ 
treatment (e,f). Numbers shown are for whole skin (c,e) and for epidermis (d,f). Mean of 3 
separate fields-of-view/mouse.  
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Figure 6. Schematic model of the main findings of the study. 
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